MD Biosciences

04/07/2026

Can s*x differences influence systemic drug exposure?

In a recent MD Biosciences study, female Göttingen minipigs showed higher systemic exposure and delayed peak concentrations following bupivacaine administration.

These findings highlight the importance of characterizing PK variability in translational models when evaluating preclinical safety.

Read the abstract in the comments.

03/25/2026

Most preclinical programs start with strong data.

✔ Target engagement
✔ Rodent efficacy
✔ Acceptable early safety

So why does clinical predictability decline as development progresses?

Many programs encounter the same translational challenges around scale, delivery, durability, and procedural variability.

We mapped where these risks most often emerge so teams can address them earlier while development decisions are still flexible.

Download the Translational Failure Map: https://hubs.la/Q045CnK40

03/17/2026

MEP recordings in our SCI pig model show that immediate post-injury electrophysiology predicts functional recovery, with representative waves captured pre and post-injury.

View poster here: https://hubs.la/Q0453l0F0

03/10/2026

Reliable translational data depends on rigorous study design, infrastructure, and standards.

Our programs are supported by AAALAC International accreditation, NIH OLAW Foreign Assurance, and a purpose-built GLP translational research facility designed to support high-quality preclinical studies.

Explore our translational research facility:
https://hubs.la/Q045D-BN0

02/26/2026

We’re proud to share that MD Biosciences is now accredited by AAALAC International.

AAALAC accreditation is a globally recognized mark of excellence in animal care and goes beyond regulatory compliance.

For our partners, this means:

✔ Independent validation of our animal care program
✔ Stronger study credibility and data reliability
✔ Reduced regulatory risk
✔ Confidence that research is conducted responsibly and ethically

High-quality science starts with high standards.
This milestone reinforces the rigor, responsibility, and excellence we bring to every program.

We’re incredibly proud of our team for reaching this milestone and grateful to the sponsors who trust us with their programs.

02/18/2026

Curious about large animal models? Learn how pigs provide more clinically relevant data than rodents in preclinical research for CNS, pain, and wound healing. 🐖

Download the full paper here: https://hubs.la/Q042Kffw0

02/10/2026

🔍 Advanced AI tools are transforming preclinical wound healing research. DeePathology’s AI-based quantitative histopathology identified and measured key healing markers in a Göttingen minipig burn model.

Download the full posters here, presented at the EWMA conference: https://hubs.la/Q03Vst-y0

02/05/2026

In many programs, early-stage data is strong:
– Target engagement is demonstrated
– Efficacy is shown in rodent models
– Initial safety assessments appear acceptable

As programs advance, predictability often decreases because key translational assumptions have not yet been addressed.

Download the Translational Failure Map here: https://hubs.la/Q03_q14v0

01/27/2026

Most preclinical programs don’t fail because the science was wrong.

Predictability is often lost later because key translational assumptions haven’t been evaluated early enough.

We mapped where this happens most often across development programs, and why it’s difficult to detect early.

Download the Translational Failure Map here: https://hubs.la/Q03_pN9K0

01/21/2026

From acute to chronic inflammation, including rheumatoid arthritis and osteoarthritis, our translational models measure immune activation, tissue changes, and therapeutic effects with clinically relevant endpoints. Explore our resources on inflammatory models here:

https://hubs.la/Q03VrcdB0

A range of preclinical inflammatory pain models from acute inflammatory pain to chronic pain associated with arthritic conditions. Preclinical CRO

01/13/2026

Join us at the Non-Opioid Pain Summit! We’re eager to connect with experts advancing non-opioid pain management and share how our preclinical models support this important research.

Reach out to set up a meeting with our team: https://hubs.la/Q03SRP2y0

01/06/2026

We are excited to introduce new models and cutting-edge tools designed to accelerate your research in 2026. From advanced large-animal studies to refined biomarker detection methods, our innovative solutions are tailored to help you break new ground. Read our 2026 service catalog here:
https://hubs.la/Q03STJJJ0

Neuroscience Discovery Services Catalog